Clinical Trial: Injectable hydrogel microspheres for sustained long-term delivery of cartilage-targeting exosomes/POSTN-Cas9 inhibit ferroptosis and ECM degradation to ameliorate osteoarthritis and a mechanistic study (China)

Posted On: 2026-08-24

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Injectable hydrogel microspheres for sustained long-term delivery of cartilage-targeting exosomes/POSTN-Cas9 inhibit ferroptosis and ECM degradation to ameliorate osteoarthritis and a mechanistic study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130604

Registration Time: 2026/08/21

Type: Observational study

Primary Sponsor: The Second Affiliated Hospital of Wenzhou Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=307980

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Injectable hydrogel microspheres for sustained long-term delivery of cartilage-targeting exosomes/POSTN-Cas9 inhibit ferroptosis and ECM degradation to ameliorate osteoarthritis and a mechanistic study (China)